Keenova Therapeutics plc financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q3 2025.

Location
Dublin 15
Fiscal year end
31 December
Latest financial report
10 Nov 2025

Quick Takeaways

  • Keenova Therapeutics plc financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q3 2025.
  • Headline metric: Return On Invested Capital -3.3%.

What Changed

  • Return On Invested Capital YoY change: <span class="text-red-600">-159%</span>.
  • Most recent SEC facts end date: 07 Nov 2025.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2025-11-07) highlights Return On Invested Capital -3.3%, Return On Equity 14.2%, and Return On Assets 4.9%.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

33.5/100

Weak Confidence high

Return On Invested Capital

-3.3%

Metric score 0.0/100

Return On Equity

14%

Metric score 36.4/100

Return On Assets

4.9%

Metric score 36.2/100

Financial Health

Current Ratio
3.23x
Quick Ratio
1.69x
Debt to Equity
1.17x

Strengths

Quick Ratio

Watchpoints

Return On Invested Capital, Return On Equity, and Return On Assets

Key metrics snapshot

Return On Equity

14%

YoY: -97%

Industry median: -43% (n=675)

View history

Return On Assets

4.9%

YoY: -219%

Industry median: -47% (n=673)

View history

Current Ratio

3.23x

YoY: +3.8%

Industry median: 3.39x (n=667)

View history

Quick Ratio

1.69x

YoY: +18%

Industry median: 1.51x (n=289)

View history

Debt-to-equity

1.17x

YoY: -30%

Industry median: 0.26x (n=530)

View history

NetIncomeLoss YoY

-1011%

YoY:

Industry median: -0.93% (n=641)

View history

Profitability

Metric Latest value YoY change
Return On Invested Capital -3.3% -159%
Return On Equity 14% -97%
Return On Assets 4.9% -219%

Financial Health

Metric Latest value YoY change
Current Ratio 3.23x +3.8%
Quick Ratio 1.69x +18%
Debt-to-equity 1.17x -30%

Growth

Metric Latest value YoY change
NetIncomeLoss YoY -1011%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 39,526,162 +101%
Weighted Average Number of Shares Outstanding, Basic 32,300,000 +64%
Weighted Average Number of Shares Outstanding, Diluted 32,300,000 +64%

Additional Metrics

Metric Latest value YoY change
Research and Development Expense $118,800,000 +17%
Operating Income (Loss) $177,000,000 -783%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $391,300,000 -1621%
Income Tax Expense (Benefit) $96,200,000 +676%
Earnings Per Share, Basic 20.81 -577%
Earnings Per Share, Diluted -9.01 -577%
Cash and Cash Equivalents, at Carrying Value $1,047,900,000 +155%
Accounts Receivable, after Allowance for Credit Loss, Current $757,900,000 +98%
Inventory, Net $1,322,300,000 +86%
Assets, Current $3,458,400,000 +101%
Deferred Income Tax Assets, Net $843,600,000 +8.6%
Property, Plant and Equipment, Net $831,600,000 +130%
Intangible Assets, Net (Excluding Goodwill) $2,560,400,000 +490%
Goodwill $7,300,000
Other Assets, Noncurrent $766,400,000 +238%
Assets $8,467,700,000 +133%
Accounts Payable, Current $165,400,000 +96%
Employee-related Liabilities, Current $146,000,000 +62%
Liabilities, Current $1,071,100,000 +93%
Long-term Debt and Lease Obligation $3,690,600,000 +113%
Accrued Income Taxes, Noncurrent $34,900,000 +36%
Other Liabilities, Noncurrent $351,100,000 +250%
Liabilities $5,316,400,000 +104%
Accumulated Other Comprehensive Income (Loss), Net of Tax $13,300,000 +375%
Retained Earnings (Accumulated Deficit) $121,400,000
Stockholders' Equity Attributable to Parent $3,151,300,000 +206%
Liabilities and Equity $8,467,700,000 +133%
Increase (Decrease) in Income Taxes $4,400,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,203,000,000 +153%
Deferred Tax Assets, Valuation Allowance $73,000,000
Depreciation $41,700,000 +13%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $306,900,000 -1460%
Property, Plant and Equipment, Gross $908,100,000 +128%
Preferred Stock, Shares Issued 0
Preferred Stock, Shares Authorized 500,000,000 0%
Unrecognized Tax Benefits $34,200,000 +15%
Additional Paid in Capital $3,016,200,000 +152%
Preferred Stock, Shares Outstanding 0
Amortization of Intangible Assets $88,400,000 +7.4%
Preferred Stock, Par or Stated Value Per Share 0.01 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY